Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Acorda Therapeutics (ACOR)

0.7331   -0.03 (-3.97%) 08-07 14:57
Open: 0.7583 Pre. Close: 0.7634
High: 0.7599 Low: 0.708
Volume: 1,653,437 Market Cap: 35M
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.811 - 0.814 0.814 - 0.816
Low: 0.683 - 0.686 0.686 - 0.689
Close: 0.755 - 0.76 0.76 - 0.765

Technical analysis

as of: 2020-08-07 2:23:38 PM
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Target: Six months: 1.03     One year: 1.23
Support: Support1: 0.60    Support2: 0.50
Resistance: Resistance1: 0.88    Resistance2: 1.05
Pivot: 0.72
Moving Average: MA(5): 0.70     MA(20): 0.72
MA(100): 0.84     MA(250): 1.68
MACD: MACD(12,26): -0.02     Signal(9): -0.02
Stochastic oscillator: %K(14,3): 29.70     %D(3): 22.25
RSI: RSI(14): 50.22
52-week: High: 4.46  Low: 0.60  Change(%): -74.2
Average Vol(K): 3-Month: 248174  10-Days: 282036

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
ACOR has closed below upper band by 47.0%. Bollinger Bands are 10.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 07 Aug 2020
Analysts Offer Important Insight on Acorda Therapeutics, Inc. (ACOR) - Stocks Register

Thu, 06 Aug 2020
Acorda Therapeutics Inc. (ACOR) Soars 7.57% on August 06 -

Thu, 06 Aug 2020
Acorda Therapeutics Inc. (NASDAQ:ACOR) Stock is Soaring, Here is Why - The Oracle Dispatch

Wed, 05 Aug 2020
Key Indicators to Know Before Trading Acorda Therapeutics Inc. as (ACOR) Declares Q2 - Frisco Herald

Wed, 05 Aug 2020
Acorda Therapeutics Inc. (ACOR) Soars 10.89% on August 05 -

Tue, 04 Aug 2020
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2020 Results - Earnings Call Transcript - Seeking Alpha

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 48
Shares Float (M) 43
% Held by Insiders 1.49
% Held by Institutions 116.94
Shares Short (K) 9,120
Shares Short P. Month (K) 8,390

Stock Financials

EPS -4.885
EPS Est This Year 1.750
EPS Est Next Year 0.700
Book Value (p.s.) 6.430
Profit Margin -131.45
Operating Margin -64.00
Return on Assets (ttm) -7.1
Return on Equity (ttm) -53.1
Qtrly Rev. Growth -36.3
Gross Profit (p.s.) 3.284
Sales Per Share 3.676
EBITDA (p.s.) -1.535
Qtrly Earnings Growth
Operating Cash Flow (M) -89
Levered Free Cash Flow (M) -123

Stock Valuations

PE Ratio -0.15
PEG Ratio
Price to Book value 0.11
Price to Sales 0.20
Price to Cash Flow -0.39

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.